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Abstract: Reliable serum biomarkers are of immense need for diagnostic purposes of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS)—a disabling and complex disease for which
diagnosis is mainly based on clinical symptoms. The aim of this study was to evaluate a possible
diagnostic potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls.
Analyses of human activin B level in plasma samples were performed using a validated human
activin B ELISA assay. The results of the study show that activin B levels did not differ statistically
significantly between ME/CFS patients and healthy controls (p = 0.6511). No gender or age-related
differences in activin B levels were observed in the ME/CFS group and healthy controls. The level
of activin B tended to decrease with increasing visual analogue scale score (r = −0.2004; p = 0.5085)
nevertheless the results obtained so far does not support the clinical utility of activin B as a biomarker
for ME/CFS.
Keywords: ME/CFS; human activin B; visual analogue scale
1. Introduction
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complicated,
chronic disease mainly characterized by severe fatigue with many clinical symptoms related
to autonomic nervous system imbalance, cognitive impairment, immune and endocrine
dysfunction [1]. The prevalence of ME/CFS worldwide varies from 0.1% up to 2.2%
depending on the applied diagnostic criteria [2–4]. However, there are no European-wide
estimates of disease burden [5].
The disease affects all ages, races and socioeconomic groups and some studies show
that approximately three to four times as many women as men present with symptoms [6].
Despite many years of molecular and clinical research worldwide, there is still no unified
definition for this heterogeneous disease. Another aspect of the complexity of ME/CFS
is that no objective parameters or diagnostic markers exist to ensure an exact clinical
assessment of the patient. However, the most widely used clinical definitions in clinical
research are the Fukuda criteria and the International Consensus criteria, both of which
demonstrate an inability to separate ME from CFS [7,8]. Genetic predisposition, stress,
trauma, exposure to toxins, physical activity and rest ratio, as well as viral infections have
been considered as potential etiological factors for ME/CFS [9,10]. The disease is mainly
characterized by severe fatigue, post-exertional malaise, un-refreshing sleep, memory loss,
difficulty concentrating, sore throat, lymphadenopathy, muscle pain and headaches. The
pathomechanisms of ME/CFS are still under investigation, and there are no standardized
biological markers or tests for diagnostics; therefore, even the existence of this medical
diagnosis has been questioned for a long time [10–12]. The pathogenesis of ME/CFS is
likely multi-factorial and various microbial and viral infections are possible trigger factors
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of ME/CFS. Still, a single infectious representative has not yet been confirmed and the role
of viral infections in ME/CFS remains obscure as there is no proven correlation between
ME/CFS severity and the stage of infectious process yet.
It is extremely important to develop simpler diagnostic tools from routine data to
assist health professionals to diagnose ME/CFS and to monitor therapeutic approaches.
Examination of the diagnostic potential of serum biomarkers would allow for the stratifica-
tion of ME/CFS patients and allow patients to both seek appropriate therapy and evaluate
its efficacy in an efficient manner.
As regards possible ME/CFS serum biomarkers, activin B has recently been added
to the list. Activin B was stated as a possible marker that could distinguish ME/CFS
cases and healthy controls, showing that a higher median of activin B level is observed in
healthy controls compared to ME/CFS patients [13]. However, more multi-centre studies
demonstrating the previously described tendency with large participant cohorts are needed
to acknowledge activin B as a sensitive and specific serum biomarker. Moreover, activin B
also had a tendency to predict the severity of the symptoms in patients with ME/CFS. This
finding was observed using weighted standing time (WST) severity classes and analysing
them together with other serum biomarkers, for example activin A or follistatin [13].
Activins, members of the transforming growth factor β (TGF-β) superfamily, were
first isolated from porcine ovarian follicular fluid and identified as activating factors for
the release of follicle stimulating hormone [14]. Different additional roles have since been
identified for these proteins, including broad and complex effects on cell growth and differ-
entiation, regulation of embryogenesis, development of the reproductive system, wound
healing, stem cell differentiation and regulation of immune response [15,16]. Activins are
disulfide-linked dimeric molecules in structure composed of βA- and βA-subunits (activin
A), βB- and βB-subunits (activin B), or βA and βB-subunits (activin AB) [14]. Activin A
has long been known to be a critical regulator of inflammation and immunity, and similar
roles are now emerging for activin B, with which it shares 65% sequence homology [17].
These molecules and their binding protein, follistatin, are widely expressed, and their
production is increased in many acute and chronic inflammatory conditions. Synthesis
and release of the activins are stimulated by inflammatory cytokines, Toll-like receptor
ligands, and oxidative stress. So far, activin A has been the most extensively studied
TGF-b family member while activin B has received relatively little attention compared with
activin A. In many cases activin B shares several of the functions of activin A; however,
it may also exert functionally distinct effects from those of activin A [18]. There are data
available showing that activin B production is increased in some cell types in response to
inflammatory stimuli, most notably hepatic stellate cells, pituitary cells, and microglial
cells [19,20]. Activin B regulates cellular migration by inducing actin stress fiber formation.
Activins have been found in most tissues including placenta, reproductive organs, bone
marrow, and brain [21].
Some studies suggest that activin may be an important mediator involved in the
inflammatory response in the brain. Activin in microglia was first demonstrated during
meningitis [22], however the role of activin in the brain microglia cells has not been fully
understood. The findings of Sugama et al., where they used cultured microglial cells
and rat brain, strongly suggest that activin may have inhibitory functions for microglial
activation [20]. Activin is produced when microglia becomes activated, and this process is
a major part of neuroinflammation, which is one of main pathogenetical mechanisms in
myalgic encephalomyelitis. Knowing the widespread localization of activins, it has been
reported that in a variety of tissues activin controls numerous processes and conditions,
including inflammation, osteoporosis, stimulation of follicle stimulating hormone release
from the pituitary, folliculogenesis in the ovary, erythroid differentiation, nerve cell survival,
and tumour and embryonic development [23,24]. The fact that activin B can promote a loss
of muscle mass [25] and is involved in immune dysregulation point out that it could be
involved in the pathogenesis of ME/CFS, considering that muscle weakness and pain are
included in the diagnostic criteria [26].
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2. Materials and Methods
In total 134 patients [42 males (23–76 years old) and 92 females (23–68 years old)]
with clinically diagnosed ME/CFS corresponding to 1994 Fukuda criteria and 54 healthy
controls [41 males (18–65 years old) and 13 females (18–61 years old)] were recruited
for this study. Healthy blood donors were included in the study as a control group.
Plasma samples were always processed and stored according to the following standards:
samples were frozen in aliquots and stored at −80 ◦C until the analyses. Human activin
B concentration in blood plasma samples was analysed using the commercially available
ELISA kit (LifeSpan BioSciences, Seattle, WA, USA). The assay measures ‘total’ activin
B and is based on the sandwich ELISA principle. It is specific for the use of human
plasma samples with the lower limit of detection being 15.63 pg/mL. All plasma samples
were analysed in duplicate. The inter-assay and intra-assay CV were <6% and <6.15%
respectively. Total duration of assay was 4 h. Briefly, all reagents, samples and standards
were prepared and 100 µL was added to each well pre-coated with antibody specific for
activin B. After an incubation of 1.5 h at 37 ◦C, 100 µL of biotin-conjugated antibody
specific for activin B was added. Following an incubation of 1 h at 37 ◦C, 100 µL of an
avidin-horseradish peroxidase conjugate was added and incubated for 30 min at 37 ◦C.
Following this, 90 µL of tetramethylbenzidine substrate was added. This was followed by
an incubation of 15 min at 37 ◦C. Lastly, 50 µL of stop solution was added and the plate
was read at 450 nm using Microplate Reader Thermo Multiskan Ascent, USA.
The study design was approved by the Ethical Committee of Rı̄ga Stradin, š University
(Ethical code Nr.6-1/05/33 and date of approval 30.04.2020.) and written consent was
obtained from all patients.
Between-group comparison was done by non-parametric Mann–Whitney U test or
Kruskal–Wallis test followed by two-stage step-up method of Benjamini, Krieger, and
Yekutieli as the post-hoc procedure. Statistical significance was set at p < 0.05.
3. Results
3.1. Human Activin B Concentration
Human activin B concentration in plasma samples was above 15.63 pg/mL in 13 out
of 134 (9.7%) patients with ME/CFS and in 4 out of 54 (7.4%) healthy controls. For most
patients—121 (96.69%)—and also most controls—50 (92.6%)—activin B concentration was
below 15.63 pg/mL. Mean activin B concentration was compared between the ME/CFS
patients and healthy controls. The study results did not show any statistically significant
difference in activin B plasma level between ME/CFS cases and healthy controls (p = 0.6511)
(Figure 1).
Figure 1. Activin B level in blood plasma samples of patients with ME/CFS and control group
individuals.
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The level of activin B plotted against gender did not show any differences between
male and female among ME/CFS patients (p = 0.0578) (Figure 2). Additionally, in the
control group, there were no differences in activin B concentration between males compared
to females (p = 0.5618) (Figure 2). When analysing the gender differences in activin B levels
in ME/CFS patients compared to control men and women, no difference was found
(p = 0.8367 and p = 0.6116 respectively) (Figure 2).
Figure 2. The levels of activin B in patients with ME/CFS and controls plotted against gender.
The level of activin B plotted against age did show that activin B level does not
change regarding the aging process of patients with ME/CFS and also controls (Figure 3).
Additionally, no differences were observed between patients and controls in all age groups.
Figure 3. The levels of activin B in patients with ME/CFS and controls plotted against age.
3.2. Clinical Data of ME/CFS Patients with Human Activin B Level above and below 15.63 pg/mL
As to the clinical characteristics, apart from the Fukuda criteria, we also investigated
additional symptoms and patterns of fatigue to both investigate the core symptoms in
our cohort, as well as understand whether there are any differences in fatigue pattern
regarding activin B level. To achieve the goal, patients were interviewed using adapted
semi-structured interview questions created by Minnock, et al. [27]. The questions were
structured in 6 sections: causes and triggers of fatigue; character of fatigue; current symp-
toms; comorbidities; solutions for fatigue; and its influence on work disability. Multiple
answers were proposed for each question. We used the Athens Sleep Questionnaire [28],
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including problems in 6 or more of the following sleep-related questions: impaired sleep
induction, awakening during the night, final awakening earlier than desired, insufficient
total duration of sleep, impaired quality of sleep and impaired sense of well-being and/or
physical or mental functioning during the day, as well as sleepiness during the day. Visual
analogue scale (VAS), ranging from 0 to 10, was also measured for all patients. To compare
the clinical differences in each section of our questions considering activin B level, we
divided respondents into two groups—with activin B level above 15.63 pg/mL (activin B
positive group) and activin B level below 15.63 pg/mL (activin B negative group).
As to the possible trigger of fatigue, the most prevalent was considered physical work
(38%), sleep disturbances (24%), mental work (22%), diet problems (9%) and emotional
stressors (7%) in the activin B positive group, compared to mental work (31%), physical
work (28%), eating disturbances (13%), sleep disturbances (16%), co-morbidities (6%) and
drugs (6%) in the activin B negative group. In both groups, fatigue had been prevalent at
least for the last 6 months, but for the most part fatigue had been present at least for the
last year (in 67% and 70% of patients in the activin B positive and activin B negative group,
respectively). For all of the participants, fatigue was unrelieved by rest and almost all in
both groups (83% and 61% in activin B positive and negative group, respectively) admitted
that fatigue was constant throughout the day without any changes in severity depending
on the time of the day. In the activin B positive group, fatigue was more severe in the
evening (17%), compared to the activin B negative group, where it was reported as more
severe in the morning (22%) or variable throughout the day (17%). All of the participants
in both groups answered that there have been periods when fatigue had been persistent
for several days, weeks or months without any explicable reason.
Comparing the most common clinical symptoms that the respondents had felt during
the period of the last 6 months besides fatigue, in both groups the five most prevalent symp-
toms from 22 proposed in the questionnaire were comparable: headache (100%), myalgia
(92%), difficulty concentrating (92%) and arthralgia (83%) in the activin B positive group
and myalgia (96%), difficulty concentrating (83%) arthralgia (71%) and sleep disturbances
(58%) in the activin B negative group.
Regarding the reduction in occupational, personal, social, or educational activities, all
of the participants reported that the above-mentioned activities were affected because of
fatigue. Most of them have resigned (50% in activin positive and 52% in activin negative
group, respectively), have changed their duties or reduced their workload (25% in activin
positive and 35% in activin negative group, respectively), but the minority have not changed
anything in their occupational activities (25% in activin positive and 13% in activin negative
group, respectively). All of the participants answered that they factor in fatigue when
making future plans and that their family members and/or friends have noticed fatigue
and have tried to talk about it to the respondents. Besides that, some differences were
noted in terms of family history of fatigue—there were no known relatives suffering from
fatigue in the activin B positive group, whereas 22% noted at least one relative with similar
symptoms in the activin B negative group.
In the assessment of subjective solutions to reduce the symptoms of fatigue, in both
groups the majority of respondents consider physical activity or sleep hygiene to be the
most effective (54% and 50% in the activin B positive and negative group, respectively).
Pharmaceutical drugs were considered to be effective in the activin B positive group (38%),
comparing to the activin B negative group (17%). 33% in the activin B negative and 8% in
the activin B positive group have not found any solutions to their symptoms.
VAS was measured for all patients and correlation between VAS and activin B level
was conducted. Comparing the mean VAS score, it was 7 in both activin B positive and
activin B negative groups. Apart from that, the scores were also equally distributed among
both groups (Figure 4, showing no significant differences).
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Figure 4. Symptom severity grading score compared in activin B positive and activin B negative
groups.
To be able to statistically compare the subjective severity of the clinical symptoms in
both groups we decided to grade the answers from the questionnaire, taking into account
the symptom count, the duration of fatigue (the longer the period of fatigue, the higher
the grade), the impact of fatigue on quality of life, the pattern of fatigue and whether
any solutions to ease the symptoms were found. Although the graph shows variations in
distribution between groups, the obtained results did not show significant differences in
subjective fatigue severity scores in activin B positive and negative groups (Figure 4).
Regarding the level of activin B, it was found to decrease with increasing VAS score
(Figure 5); however no statistical significance was observed (p = 0.5085).
Figure 5. Correlation of visual analogue scale with activin B level.
4. Discussion
Although ME/CFS has been under investigation for more than 30 years, progress
on the examination of the diagnostic potential of serum biomarkers has not been rapid.
Trusty serum biomarkers for ME/CFS are essential and necessary for this disabling and
complex disease. According to the available data in the literature so far, the role of activin
B in ME/CFS has been studied only by one group of researchers from The National Centre
for Epidemiology and Public Health, Australia where 45 ME/CFS cases and 17 healthy
controls were analysed [26]. By comparing ME/CFS patients with healthy controls, the
researchers concluded that a statistically significant increase in activin B level is found in
those with ME/CFS (p < 0.0001). Despite the relatively small sample size analysed, the
authors stated that activin B could help to distinguish ME/CFS patients from those without
the condition. Furthermore, the same group of scientists a few years later published a study
with an increased ME/CFS group of 85 cases and concluded that activin B level showed
a statistically significant decrease in those diagnosed with ME/CFS [13]. Based on data
available in the literature about activin B in cases of ME/CFS, we tested the diagnostic
potential of activin B by directly comparing 134 cases of ME/CFS with 54 healthy controls.
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In this study there was no statistically significant difference found regarding the level of
activin B between ME/CFS cases and healthy controls, thereby limiting the use of activin B
in the diagnostics of ME/CFS. The obtained study results show that the concentration of
activin B in patients with ME/CFS and healthy controls do not significantly differ between
male and female (p = 0.0578; p = 0.5618, respectively). Previously published data also
show no significant difference between healthy male and female serum samples. However,
significant differences were found between healthy values and the other groups (women
undergoing IVF procedures, men with marked semen abnormalities and other) of the same
gender [29]. Our results demonstrate that there were no age-related differences of activin B
concentration in healthy adult males. Ambiguous data have been published showing that
some studies did not show a difference in activin B levels between healthy men in the age
group [29] while others showed an increase in activin B levels in older men [30].
Data published so far show a tendency for activin B to decrease with increasing age of
a healthy adult female [29]. That may be associated with a decrease in the number of antral
follicles in the ovaries with age, as the antral follicles have been found to express the βB
subunit of activin B [31,32]. In this study, the results show that there was no relationship of
activin B concentration with age in healthy adult females.
The clinical relevance of activin B has not been clear in ME/CFS; however, the cor-
relation between VAS and activin B level was conducted. The concentration of activin B
decreases with increasing VAS score (r = −0.2004); however no statistical significance was
observed (p = 0.5085).
Many factors regulate activin B bioactivity but follistatin is considered as the major
regulator [33]. As activin B can bind to follistatin it is very important to choose an assay
which measures total activin B, not only “free” activin B, which is unbound to binding
protein such as follistatin. The assay we choose is appropriate, because it measures total
activin B. The strength of our study is the sufficient number of patients analysed. A
limitation of our study can be considered the fact that no simultaneous comparative
evaluation of activin B′s closely related sister molecule, activin A, which is also a protein
associated with inflammation and tissue stress, has been performed.
Although different ME/CFS diagnostic criteria were used (Canadian consensus criteria
in the study mentioned below [26] and Fukuda criteria in our study), comparing the clinical
symptoms in the activin B positive group to the ones reported in the cross sectional study
regarding activin B [26], the respondents apart from post-exertional fatigue present with
difficulty concentrating and sleep disturbances in both cohorts, although respondents
in our study were more prone to have myalgia, arthralgia and headache (compared to
less than 10% in the study mentioned [26]). There were no patients presenting with new
allergies or arrhythmias in our study, compared to approximately 50% of study participants
having these symptoms in the other cohort. As stated above, activin B has the potential
role to induce muscle wasting and pain [25]. Nevertheless, one of the core symptoms in the
activin B positive group was myalgia, reported by 92%. The fact that 96% reported having
it in the activin B negative group may imply that activin B does not influence the clinical
presentation of muscle pain in ME/CFS patients. This finding is also substantiated by the
fact that the VAS score did not show any statistically significant differences in both groups
and even tends to decrease in the activin B positive group. Although we did not find any
significant differences in clinical presentation of symptoms in both activin B positive and
negative groups, more reports comparing the symptoms in both groups would be needed.
5. Conclusions
Results obtained in our study do not agree with the results of previously published
works and do not confirm the clinical applicability of activin B as a biomarker for ME/CFS.
Clinically, the respondents with increased activin B levels showed a tendency to have a
lower VAS score, although more data is needed to evaluate the correlation.
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